Page last updated: 2024-12-05

paramethadione

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Paramethadione is an anticonvulsant drug that was originally used to treat epilepsy. It is a cyclic urea derivative that acts as a GABAergic agent, meaning it enhances the activity of the neurotransmitter gamma-aminobutyric acid (GABA). GABA is an inhibitory neurotransmitter that helps to regulate neuronal activity. Paramethadione was first synthesized in the 1940s and was introduced as a treatment for epilepsy in the 1950s. However, its use has declined significantly since the 1970s due to the availability of newer and safer anticonvulsant medications. Paramethadione is still studied for its potential therapeutic effects, but its use in clinical practice is limited. It is important to note that paramethadione can cause serious side effects, including liver damage, bone marrow suppression, and Stevens-Johnson syndrome. Paramethadione is also known to interact with other medications, so it is important to talk to your doctor before taking it.'

paramethadione: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID8280
CHEMBL ID1100
CHEBI ID7921
SCHEMBL ID34857
MeSH IDM0047469

Synonyms (72)

Synonym
chebi:7921 ,
nsc-760129
CHEMBL1100
5-ethyl-3,5-dimethyl-1,3-oxazolidine-2,4-dione
parametadione [dcit]
einecs 204-098-8
brn 0127715
paramethadionum [inn-latin]
3,5-dimethyl-5-ethyloxazolidine-2,4-dione
hsdb 3245
parametadiona [inn-spanish]
a 348
isoethadione
5-ethyl-3,5-dimethyl-2,4-oxazolidinedione
paradione
2,4-oxazolidinedione, 5-ethyl-3,5-dimethyl-
paramethadione
115-67-3
C07411
DB00617
parametadione
paradione (tn)
paramethadione (inn)
D00495
NCGC00183600-01
HMS3264I11
5-ethyl-3,5-dimethyloxazolinedione
AKOS006239791
nsc760129
pharmakon1600-01505456
nsc 760129
4-27-00-03255 (beilstein handbook reference)
unii-z615frw64n
parametadiona
paramethadionum
paramethadione [usp:inn:ban]
z615frw64n ,
paramethadione [vandf]
paramethadione [who-dd]
paramethadione [mart.]
paramethadione [inn]
paramethadione [mi]
128557-52-8
paramethadione [hsdb]
5-ethyl-3,5-dimethyloxazolidine-2,4-dione
paramethadione [orange book]
gtpl7261
CCG-213441
SCHEMBL34857
5-ethyl-3,5-dimethyl-1,3-oxazolidine-2,4-dione #
VQASKUSHBVDKGU-UHFFFAOYSA-N
AB01563081_01
isoethadione; paradione
2-nitro-3-hydroxybenzoic acid
DTXSID8023420 ,
SR-05000002060-1
sr-05000002060
5-ethyl-3,5-dimethyloxazolidine-2.4-dione
SBI-0206930.P001
Q3895202
Z1198155421
BRD-A22128695-001-01-8
NCGC00183600-04
EN300-255078
CS-0013725
HY-B1721
paramethadione (mart.)
parametadiona (inn-spanish)
n03ac01
dtxcid703420
paramethadionum (inn-latin)
paramethadione (usp:inn:ban)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
anticonvulsantA drug used to prevent seizures or reduce their severity.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
oxazolidinoneAn oxazolidine containing one or more oxo groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID227699Virtual screen for compounds with anticonvulsant activity2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (88.24)18.7374
1990's0 (0.00)18.2507
2000's2 (11.76)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.60 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index36.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (5.88%)4.05%
Observational0 (0.00%)0.25%
Other16 (94.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]